FDA advisory panel votes overwhelmingly against MDMA therapy for PTSD By Olivia Goldhill and Meghana Keshavan

In a surprisingly strong rejection of the first psychedelic therapy to come before the FDA, a scientific advisory panel on Tuesday overwhelmingly voted against the use of MDMA for treating PTSD. At the end of a nine-hour meeting marked by sometimes-emotional testimony, the advisory committee voted 10-2 that the data do not show MDMA is effective in treating PTSD. The decision came after members critiqued the methodology of clinical trials by Lykos Therapeutics, which is seeking FDA approval for MDMA, and therapist oversight, rather than the drug itself. FDA advisory panel votes overwhelmingly against MDMA therapy for PTSD Olivia Goldhill Meghana Keshavan By Olivia Goldhill and Meghana Keshavan June 4, 2024 https://www.statnews.com/2024/06/04/fda-advisory-panel-mdma-therapy-ptsd/?utm_campaign=breaking_news&utm_medium=email&_hsenc=p2ANqtz-8CUpnjlOmzAZ9Tokz4Dw04xJ0dRLZGjz6zQI7AtLtF0JiX5oFFnesHKIY5zb3B0FGkUK-7d-8s-kf0wcVluYMecqzz-A&_hsmi=310183146&utm_content=310183146&utm_source=hs_email